FrieslandCampina Ingredients, the global innovator in healthy and functional ingredients for early life nutrition, has recently received Chinese Ministry of Agriculture and Rural Affairs (MARA) approval of its production strain of Lacto-N-Tetraose (LNT). This step of the approval, which follows the MARA’s approval of the company’s Aequival® 2’-FL ingredient, means that this ingredient will move to the final stage of the approval process, opening the doors for this human milk oligosaccharide (HMO) to be introduced into China – the world’s largest infant milk formula market.
Once both these ingredients have achieved “final nutrition fortifier” approval in China – the next and final step in the approval process – FrieslandCampina Ingredients will become the sole provider of both HMOs and galacto-oligosaccharides (GOS) in China, a unique position which will enable brands to unlock exciting new opportunities to differentiate their products by providing complementary benefits.
The news comes as FrieslandCampina Ingredients’ Aequival® LNT also secures self-affirmed Generally Recognised as Safe (GRAS) status in the US, the first of a two-step FDA approval.
Following full FDA approval, the company will be able to provide the gut-supporting benefits of LNT for infant nutrition to customers in the US. This achievement, coupled with the recent MARA approval in China, solidifies FrieslandCampina Ingredients’ position as a global leader in gut health ingredients.
Supporting gut health when it matters most
The gut plays a pivotal role in infant health and well-being. Early life gut development and maturation, including microbiota development, is essential for the proper digestion and absorption of nutrients, development of the immune system and to ensure a first line of defence against threats from the external environment. LNT is one such gut–supporting ingredient, with a growing bank of scientific research supporting its benefits.
LNT has been proven to stimulate the growth of Bifidobacteria, reduce attachment of the parasite Entamoeba histolytica, a parasite known to cause gut issues, and inhibit the growth of group B streptococcus.
The inclusion of gut health-supporting ingredients as a value-add in infant milk formulas is being influenced by the growing trend towards premiumisation, which is seeing brands increasingly leverage additional bioactive components with proven benefits for formula fed infants – particularly in markets such as China. Plus, as consumers become more aware of the importance of good gut health – 80% of parents of infants say it is a priority – ingredients like HMOs are in high demand. In fact, 45% parents in China find formulas with more HMOs appealing.
This approval means that brands will soon be able to combine FrieslandCampina Ingredients’ LNT, 2’-FL and GOS ingredients to increase the diversity of oligosaccharide structures in their formulations, tapping into both the growing interest in infant gut health and the surge in demand for premium infant milk formulas.
A significant step forward
According to Cindy Zhao, General Manager at FrieslandCampina Ingredients China, “This news marks a significant milestone for us as a company and for the early life nutrition sector in China and the US. Both the MARA and self-affirmed GRAS approvals of the production strain of our LNT brings us one step closer to meeting consumers’ increasing demand for premium, gut-supporting infant milk formulas that provide benefits for babies when breastfeeding isn’t an option.”
Zhao added that these approvals, secured through a rigorous regulatory process, further highlights FrieslandCampina Ingredients’ status as a reliable and trusted supplier to the early life nutrition market.
For more information, click on: FrieslandCampina Ingredients (local APAC office)